These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 14727944)

  • 1. Defining the role of calcium channel antagonists in heart failure due to systolic dysfunction.
    Mahé I; Chassany O; Grenard AS; Caulin C; Bergmann JF
    Am J Cardiovasc Drugs; 2003; 3(1):33-41. PubMed ID: 14727944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of calcium channel antagonists in the treatment of pediatric hypertension.
    Sahney S
    Paediatr Drugs; 2006; 8(6):357-73. PubMed ID: 17154643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving role of calcium channel blockers in heart failure.
    Pieper JA
    Pharmacotherapy; 1996; 16(2 Pt 2):43S-49S. PubMed ID: 8668605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.
    Opie LH
    Cardiovasc Drugs Ther; 1988 Mar; 1(6):625-56. PubMed ID: 3154329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of calcium channel antagonists for cardiovascular disease.
    Yedinak KC
    Am Pharm; 1993 Aug; NS33(8):49-64; quiz 64-6. PubMed ID: 8213473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium channel blockers in heart failure.
    Elkayam U
    Cardiology; 1998; 89 Suppl 1():38-46. PubMed ID: 9570428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine.
    Little WC; Cheng CP; Elvelin L; Nordlander M
    Cardiovasc Drugs Ther; 1995 Oct; 9(5):657-63. PubMed ID: 8573548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of calcium antagonists in the management of congestive heart failure: initial experience with lacidipine.
    de Vries RJ; Dunselman PH
    J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S33-9. PubMed ID: 8852543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heart failure due to diastolic dysfunction: the treatment principles].
    Pinamonti B; di Lenarda A; Sinagra G
    Ital Heart J Suppl; 2000 Apr; 1(4):469-80. PubMed ID: 10832133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium channel blockers in cardiac failure.
    Mahon N; McKenna WJ
    Prog Cardiovasc Dis; 1998; 41(3):191-206. PubMed ID: 9872606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ; Domínguez Rodríguez A
    Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines.
    de Vries RJ; van Veldhuisen DJ; Dunselman PH
    Am Heart J; 2000 Feb; 139(2 Pt 1):185-94. PubMed ID: 10650289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug treatment of stable angina pectoris in the elderly: defining the place of calcium channel antagonists.
    Kumar S; Hall RJ
    Drugs Aging; 2003; 20(11):805-15. PubMed ID: 12964887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases.
    Lüscher TF; Wenzel RR; Moreau P; Takase H
    Cardiovasc Drugs Ther; 1995 Aug; 9 Suppl 3():509-23. PubMed ID: 8562468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists.
    Zannad F; Matzinger A; Larché J
    Am J Hypertens; 1996 Jul; 9(7):633-43. PubMed ID: 8806975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
    Noll G; Lüscher TF
    Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium channel blockers in congestive heart failure: theoretic considerations and clinical experience.
    Colucci WS; Fifer MA; Lorell BH; Wynne J
    Am J Med; 1985 Feb; 78(2B):9-17. PubMed ID: 3976695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of calcium antagonists in ischaemic heart disease.
    Pepine CJ
    Eur Heart J; 1995 Aug; 16 Suppl H():19-24. PubMed ID: 8846801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac benefits of ACE inhibitors and calcium antagonists alone and in combination.
    Sleight P
    J Cardiovasc Pharmacol; 1994; 23 Suppl 1():S39-42. PubMed ID: 7519696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.